TY - JOUR
T1 - Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease
T2 - A randomized controlled trial
AU - Ezpeleta, Mark
AU - Gabel, Kelsey
AU - Cienfuegos, Sofia
AU - Kalam, Faiza
AU - Lin, Shuhao
AU - Pavlou, Vasiliki
AU - Song, Zhenyuan
AU - Haus, Jacob M.
AU - Koppe, Sean
AU - Alexandria, Shaina J.
AU - Tussing-Humphreys, Lisa
AU - Varady, Krista A.
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2023/1/3
Y1 - 2023/1/3
N2 - Innovative non-pharmacological lifestyle strategies to treat non-alcoholic fatty liver disease (NAFLD) are critically needed. This study compared the effects of alternate day fasting (ADF) combined with exercise to fasting alone, or exercise alone, on intrahepatic triglyceride (IHTG) content. Adults with obesity and NAFLD (n = 80, 81% female, age: 23–65 years) were randomized to 1 of 4 groups for 3 months: combination of ADF (600 kcal/2,500 kJ “fast day” alternated with an ad libitum intake “feast day”) and moderate-intensity aerobic exercise (5 session per week, 60 min/session); ADF alone; exercise alone; or a no-intervention control group. By month 3, IHTG content was significantly reduced in the combination group (−5.48%; 95% CI, −7.77% to −3.18%), compared with the exercise group (−1.30%; 95% CI, −3.80% to 1.20%; p = 0.02) and the control group (−0.17%; 95% CI, −2.17% to 1.83%; p < 0.01) but was not significantly different versus the ADF group (−2.25%; 95% CI, −4.46% to −0.04%; p = 0.05). Body weight, fat mass, waist circumference, and alanine transaminase (ALT) levels significantly decreased, while insulin sensitivity significantly increased in the combination group compared with the control group. Lean mass, aspartate transaminase (AST), HbA1c, blood pressure, plasma lipids, liver fibrosis score, and hepatokines (fetuin-A, FGF-21, and selenoprotein P) did not differ between groups. Combining intermittent fasting with exercise is effective for reducing hepatic steatosis in patients with NAFLD but may offer no additional benefit versus fasting alone.
AB - Innovative non-pharmacological lifestyle strategies to treat non-alcoholic fatty liver disease (NAFLD) are critically needed. This study compared the effects of alternate day fasting (ADF) combined with exercise to fasting alone, or exercise alone, on intrahepatic triglyceride (IHTG) content. Adults with obesity and NAFLD (n = 80, 81% female, age: 23–65 years) were randomized to 1 of 4 groups for 3 months: combination of ADF (600 kcal/2,500 kJ “fast day” alternated with an ad libitum intake “feast day”) and moderate-intensity aerobic exercise (5 session per week, 60 min/session); ADF alone; exercise alone; or a no-intervention control group. By month 3, IHTG content was significantly reduced in the combination group (−5.48%; 95% CI, −7.77% to −3.18%), compared with the exercise group (−1.30%; 95% CI, −3.80% to 1.20%; p = 0.02) and the control group (−0.17%; 95% CI, −2.17% to 1.83%; p < 0.01) but was not significantly different versus the ADF group (−2.25%; 95% CI, −4.46% to −0.04%; p = 0.05). Body weight, fat mass, waist circumference, and alanine transaminase (ALT) levels significantly decreased, while insulin sensitivity significantly increased in the combination group compared with the control group. Lean mass, aspartate transaminase (AST), HbA1c, blood pressure, plasma lipids, liver fibrosis score, and hepatokines (fetuin-A, FGF-21, and selenoprotein P) did not differ between groups. Combining intermittent fasting with exercise is effective for reducing hepatic steatosis in patients with NAFLD but may offer no additional benefit versus fasting alone.
KW - aerobic exercise
KW - alternate day fasting
KW - insulin resistance
KW - intermittent fasting
KW - non-alcoholic fatty liver disease
KW - obesity
KW - weight loss
UR - http://www.scopus.com/inward/record.url?scp=85144963428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144963428&partnerID=8YFLogxK
U2 - 10.1016/j.cmet.2022.12.001
DO - 10.1016/j.cmet.2022.12.001
M3 - Article
C2 - 36549296
AN - SCOPUS:85144963428
SN - 1550-4131
VL - 35
SP - 56-70.e3
JO - Cell Metabolism
JF - Cell Metabolism
IS - 1
ER -